Epitalon and Telomerase Research: What the Studies Show and How to Verify Your Material

• ·Epitalon (also Epithalon) is the synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG), developed as an analog of epithalamin, a pineal gland extract.[5]
• ·The best-known study, Khavinson et al. (2003), reported telomerase activation and telomere elongation in cultured human somatic cells.[1]
• ·The evidence is largely from cell culture and animal studies, and much of it comes from one research school.
• ·Epitalon received a PCAC recommendation in July 2026, 7 in favor, 4 against, 1 abstention; it is not FDA-approved.[2]
• ·It belongs to a family of near-identical short peptides, so identity confirmation by mass is essential.

The identity data:

• ·Sequence. Ala-Glu-Asp-Gly (AEDG).
• ·Length. 4 residues.
• ·Molecular weight. 390.35 g/mol (C₁₄H₂₂N₄O₉).
• ·Origin. Synthetic analog of epithalamin, a bovine pineal extract.[5]

Research Material

Amino Acid Sequence

Chemical Structure

Telomeres are repetitive DNA sequences that cap chromosome ends and shorten with each cell division in most somatic cells. Telomerase, the enzyme that extends them, is largely inactive in adult somatic cells. Whether a molecule can reactivate it is a central question in cellular aging research.

Khavinson, Bondarev and Butyugov reported in the Bulletin of Experimental Biology and Medicine (2003) that adding Epitalon to telomerase-negative cultured human fetal fibroblasts induced expression of the telomerase catalytic subunit, telomerase activity and telomere elongation.[1] A follow-up from the same group in 2004 reported that treated cells continued dividing beyond the limit seen in controls, with 10 extra divisions.[6]

A 2025 study from a group at Brunel University London, outside the originating school, revisited the question in human cell lines. It reported telomere lengthening through hTERT and telomerase upregulation in normal epithelial and fibroblast cells, and through alternative lengthening of telomeres (ALT) activation in two breast cancer lines.[3] First posted as a preprint, it was published in the peer-reviewed journal Biogerontology in September 2025.

• ·Cell culture is not the organism. Telomere effects in fibroblast culture do not establish effects in tissue.
• ·Telomerase activation carries its own questions. Telomerase is active in most cancers, so reactivation is studied with attention to proliferation markers.
• ·Concentration of authorship. Much of the literature comes from the St. Petersburg Institute of Bioregulation and Gerontology and associated groups.
• ·Peptide bioregulator framework. Some of this research proposes that short peptides act by binding DNA directly. That idea is not widely accepted outside the originating school and should be treated as a hypothesis.

Epitalon belongs to a group of short "bioregulator" peptides that includes several di-, tri- and tetrapeptides with overlapping residues. Several share alanine, glutamate or aspartate, and their masses can be close. A labeling or manufacturing mix-up between them is a real risk.

How to verify:

• ·Check the observed mass on the certificate against Epitalon's expected mass, 390.35 g/mol.
• ·Check the sequence stated by the supplier: A-E-D-G.
• ·Check HPLC retention consistency between lots, if your supplier publishes chromatograms.

Epitalon was removed from FDA Category 2 in April 2026, after its nomination was withdrawn,[4] and on 24 July 2026 the PCAC recommended it for the 503A bulks list.[2]

On 23 and 24 July 2026 the FDA's Pharmacy Compounding Advisory Committee reviewed Epitalon for inclusion on the Section 503A Bulk Drug Substances List, alongside BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. FDA staff had recommended against inclusion for every substance under review, citing insufficient characterization, little or no human effectiveness evidence, and inadequate human safety data. The committee voted in favor anyway. The vote was 7 in favor, 4 against, 1 abstention.

Rulemaking would be required before any change in compounding status. The full breakdown is in our July 2026 PCAC post. What the vote does not do, per the FDA's meeting materials and the current 503A list:[7][8][9]

• ·It is non-binding. The committee advises, it does not decide. No final FDA determination has been issued and none of the six peptides appears in 21 CFR 216.23.
• ·It requires a further step. Addition to the 503A Bulks List requires formal action by the Secretary of Health and Human Services, which had not occurred as of publication.
• ·It does not make the compound an FDA-approved drug, and it establishes nothing about efficacy.
• ·It does not legitimize research-chemical retail. A compounding-list decision concerns licensed pharmacists preparing patient-specific prescriptions under Section 503A, which is a different channel entirely from research material sold in vials.

Each Epitalon lot is tested by Janoshik Analytical before sale, and the certificate is published as the laboratory reported it, verifiable on Janoshik's own site. The identity line should match the expected 390.35 g/mol; batch, HPLC purity and measured content are read live from the batch record below. Every lot is listed on the certificates of analysis page.

Published Certificate

Batch

EPI-CA-26A-01

Purity (HPLC)

98.728%

Measured content

11.56 mglabeled 10 mg

Laboratory

Janoshik

Verify on the lab’s own databaseAll published certificates

Available at Eppix Labs

Epitalon

10mg

Every batch tested by an independent laboratory, with the certificate published before sale.

From $29.99 USDIn stock